INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the third-most common cancer worldwide, with a cumulative lifetime risk of approximately 5% \[[@R1], [@R2]\], and the clinical outcome of CRC is poor, as one-third of patients who undergo curative resection die within 5 years after surgery \[[@R3]\]. To identify patients at high risk of disease recurrence, AJCC/UICC-tumor-node-metastasis (TNM) classification is employed most frequently as a prognostic classification. However, the prognostic value of this system is limited \[[@R4]\]. Therefore, genetic and molecular tumor prognostic factors have alternatively been proposed to identify patients who may be at risk for recurrence. However, none of these have been sufficiently informative for inclusion in clinical practice \[[@R5]\]. The identification of patients at high risk of disease recurrence therefore remains a major clinical issue.

As the primary host immune response against malignant tumors, tumor-infiltrating lymphocytes (TILs) have been reported to have a crucial effect on tumor progression and the clinical outcome in various types of cancer, including non-small cell lung cancer (NSCLC), colorectal, esophageal, and urothelial cancers and melanoma \[[@R6]--[@R13]\]. Furthermore, Galon et al. \[[@R14]\] reported that the density of TILs are more valuable prognostic markers than the TNM classification. However, while a number of methods have been proposed for evaluating the density of TILs, none has yet been confirmed to be optimum.

Some researchers have evaluated the density of TILs in Hematoxylin-Eosin-stained sections, and others have evaluated the density of the subset of TILs in immunohistochemical-stained sections. The methodology for evaluating the density of TILs by immunohistochemical staining differs among reports, with suggested methods as follows: selected fields (i.e. at random or focusing on hot spots), location in high-power field (i.e. in tumor stroma, intra-tumor cells, and total TILs), and location in low-power field (i.e. the invasive margin, the center of the tumor, surface of the tumor). As described above, no standard methodology for evaluating the density of TILs has yet been established. Therefore, a standardized methodology for evaluating the density of TILs is required in order to apply this biomarker in the clinical setting.

The aim of this study was to identify the optimum methodology for evaluating the density of TILs by immunohistochemical staining to help predict the prognosis of patients.

RESULTS {#s2}
=======

Patients' characteristics in the exploratory study {#s2_1}
--------------------------------------------------

The patient characteristics are listed in Table [1](#T1){ref-type="table"}. The resected specimens were pathologically classified according to the seventh edition of the UICC TNM classification of malignant tumors. The distribution of cancer stages was as follows: stage II, 72; stage III, 67 patients. Mismatch repair status was as follows: proficient, 133; deficient, seven patients. All patients were followed up regularly with physical and blood examinations, including measurements of the levels of tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), and mandatory screening using colonoscopy and computed tomography until August 2016 or death. The median follow-up period for the survivors in this study was 64.0 months (range: 6-107). Seventeen patients died during the follow-up period due to CRC.

###### Patients characteristics

                              Exploratory Group (n= 139)   Validation Group (n= 174)
  --------------------------- ---------------------------- ---------------------------
  Gender                                                   
   Male                       72                           89
   Female                     67                           85
  Age (years)                                              
   Median (range)             65 (29-89)                   69 (21-96)
  Location of primary tumor                                
   Colon                      70                           102
   Rectum                     69                           72
  Tumor depth^\*^                                          
   T1-3                       92                           117
   T4                         47                           57
  Tumor diameter (cm)                                      
   Median (range)             5.0 (1.0-11.0)               4.0 (0.8-12.0)
  Histological type                                        
   Well, Moderately           127                          162
   Poorly, Mucinous           12                           12
  Lymphatic involvement                                    
   Negative                   30                           54
   Positive                   109                          120
  Venous involvement                                       
   Negative                   113                          134
   Positive                   26                           40
  Lymph node metastases                                    
   Negative                   72                           96
   Positive                   67                           78
  Mismatch repair status                                   
   Proficient                 133                          164
   Deficient                  6                            10

^\*^: According to UICC.TNM Classification of Malignant Tumors (seventh edition).

A survival analysis for TILs^IM^ in randomly selected field in the exploratory study {#s2_2}
------------------------------------------------------------------------------------

We assessed the prognostic value of the density of TILs at the invasive margin, in which the characteristics of the tumor have been recognized to be most accurately reflected \[[@R15]\]. The densities of CD4^+^ tTILs^IM^, sTILs^IM^, and iTILs^IM^ showed no prognostic significance (Figure [1A, 1B, 1C](#F1){ref-type="fig"}). However, high-CD8^+^ tTILs^IM^ and sTILs^IM^ were significantly associated with high disease-specific survival (DSS) rates (p=0.037, p=0.030, respectively) (Figure [1D, 1E](#F1){ref-type="fig"}), although the density of CD8^+^iTILs^IM^ was not associated with the prognosis (Figure [1F](#F1){ref-type="fig"}).

![Kaplan-Meier survival curves for the disease-specific survival according to the density of CD4/CD8^+^ TILs at the invasive margin (TILs^IM^) in randomly selected fields in the exploratory study\
**(A)** CD4^+^ tTILs^IM^. **(B)** CD4^+^ sTILs^IM^. **(C)** CD4^+^ iTILs^IM^. **(D)** CD8^+^ tTILs^IM^. **(E)** CD8^+^ sTILs^IM^. **(F)** CD8^+^ iTILs^IM^. tTILs, total TILs. sTILs, TILs in tumor stroma. iTILs, TILs intra-tumor cells.](oncotarget-09-15180-g001){#F1}

A survival analysis for TILs^IM^ in hot spots in the exploratory study {#s2_3}
----------------------------------------------------------------------

In our evaluation focusing on hot spots, the densities of all TILs evaluated by each method showed no prognostic significance (Figure [2](#F2){ref-type="fig"}).

![Kaplan-Meier survival curves for the disease-specific survival according to the density of CD4/CD8^+^ TILs at the invasive margin (TILs^IM^) focusing on hot spots in the exploratory study\
**(A)** CD4^+^tTILs^IM^. **(B)** CD4^+^sTILs^IM^. **(C)** CD4^+^iTILs^IM^. **(D)** CD8^+^tTILs^IM^. **(E)** CD8^+^sTILs^IM^. **(F)** CD8^+^iTILs^IM^. tTILs, total TILs. sTILs, TILs in tumor stroma. iTILs, TILs intra-tumor cells.](oncotarget-09-15180-g002){#F2}

Correlations between the density of CD8^+^tTILs^IM^ and the clinicopathological factors in the exploratory study {#s2_4}
----------------------------------------------------------------------------------------------------------------

The density of CD8^+^tTILs^IM^ in randomly selected field exhibited no significant relationship with any of the clinicopathological parameters, except for lymph node metastasis (p=0.028) (Table [2](#T2){ref-type="table"}).

###### Correlations between the density of CD8^+^tTILs^IM^ and the clinicopathological factors

  -------------------------------------------------------------------------------------------
                          Exploratory Group\   Validation Group\                      
                          CD8+tTILs^IM^        CD8+tTILs^IM^                          
  ----------------------- -------------------- ------------------- ------- ---- ----- -------
  Gender                                                                              

   Male                   33                   39                          23   66    

   Female                 36                   31                  0.398   13   72    0.095

  Age (years)                                                                         

   \<65                   35                   30                          14   47    

   ≥65                    34                   40                  0.397   22   91    0.695

  Tumor depth^\*^                                                                     

   T1-3                   41                   51                          26   91    

   T4                     28                   19                  0.109   10   47    0.553

  Tumor diameter (cm)                                                                 

   \<5                    33                   32                          21   80    

   ≥5                     36                   38                  0.866   15   58    1.000

  Tumor location                                                                      

   Right side             19                   14                          11   47    

   Left side              50                   56                  0.325   25   91    0.843

  Histological type                                                                   

   Well, Moderate         64                   63                          32   130   

   Poorly, Mucinous       5                    7                   0.764   4    8     0.274

  Lymphatic involvement                                                               

   Negative               12                   18                          9    45    

   Positive               57                   52                  0.303   27   93    0.425

  Venous involvement                                                                  

   Negative               53                   60                          25   109   

   Positive               16                   10                  0.198   11   29    0.267

  Lymph node metastasis                                                               

   Negative               29                   43                          19   77    

   Positive               40                   27                  0.028   17   61    0.851

  CEA (ng/ml)                                                                         

   \<5                    39                   48                          22   80    

   ≥5                     30                   22                  0.163   14   56    0.851

  CA19-9 (U/ml)                                                                       

   \<37                   58                   65                          32   123   

   ≥37                    8                    5                   0.389   3    12    1.000
  -------------------------------------------------------------------------------------------

^\*^: According to UICC.TNM Classification of Malignant Tumors (seventh edition).

CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.

Correlations between the MMR status and the density of CD8^+^tTILs^IM^ in the exploratory study {#s2_5}
-----------------------------------------------------------------------------------------------

The density of CD8^+^tTILs^IM^ in randomly selected fields in MMR-D patients tended to be higher than that in MMR-P patients (p=0.077) (Figure [3A](#F3){ref-type="fig"}).

![The correlations between mismatch repair status and the density of total CD8^+^TILs at the invasive margin (CD8^+^tTILs^IM^) in randomly selected fields\
^\*^p \< 0.1, ^\*\*^p \< 0.05.](oncotarget-09-15180-g003){#F3}

Prognostic factors influencing the survival in the exploratory study {#s2_6}
--------------------------------------------------------------------

The correlations between the DSS and various clinicopathological factors are shown in Table [3](#T3){ref-type="table"}. A multivariate analysis indicated that none of the factors were independent prognostic factors for the DSS.

###### Correlations between the disease-specific survival and various clinicopathological factors in the exploratory study

                                                                             Univariate analysis   Multivariate analysis                                      
  -------------------------------------------------------------------------- --------------------- ----------------------- --------- --------- -------------- ---------
  Age (≥65 vs. \<65)                                                         2.078                 0.754-6.602             0.161     1.485     0.498-4.926    0.482
  Tumor depth (T4 vs. T1-3)                                                  2.067                 0.760-5.625             0.151     0.920     0.283-3.001    0.889
  Histological type (Poorly, Mucinous vs. Well, Moderately)                  2.327                 0.533-7.228             0.229     1.283     0.226-6.049    0.764
  Lymphatic involvement (Positive vs. Negative)                              4.522                 0.915-81.764            0.068     1.589     0.264-30.523   0.656
  Venous involvement (Positive vs. Negative)                                 3.042                 1.034-8.206             0.044     2.550     0.795-7.630    0.111
  Lymph node metastasis (Positive vs. Negative)                              5.244                 1.705-22.791            0.003     2.247     0.625-10.771   0.225
  CEA (≥5 ng/ml vs. \<5 ng/ml)                                               5.905                 2.086-20.987            \<0.001   2.922     0.881-11.308   0.080
  CA19-9 (≥37 U/ml vs. \<37 U/ml)                                            6.348                 1.968-17.975            0.004     2.730     0.598-10.723   0.184
  The density of CD8^+^tTILs^IM^ in randomly selected field (Low vs. High)   3.135                 1.092-11.216            0.033     1.886     0.567-7.424    0.308
  Mismatch repair status (deficient vs. proficient)                          \<0.001               NA                      0.223     \<0.001   0.000-33.366   \<0.999

HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; tTILs^IM^, total tumor-infiltrating lymphocytes at the invasive margin; NA, not available.

Correlation between the density of TILs^IM^ and TILs^CT^/TILs^ST^ in the exploratory study {#s2_7}
------------------------------------------------------------------------------------------

The densities of CD8^+^tTILs^CT^ and CD8^+^tTILs^ST^ were significantly associated with that of CD8^+^tTILs^IM^ in randomly selected fields (TILs^CT^ (Figure [4A](#F4){ref-type="fig"}): r=0.71, p\<0.001; TILs^ST^ (Figure [4B](#F4){ref-type="fig"}): r=0.57, p\<0.001).

![The correlations between the densities of total CD8^+^TILs at the center of the tumor (CD8^+^tTILs^CT^)/at the surface of the tumor (CD8^+^tTILs^ST^) and that of total CD8^+^TILs at the invasive margin (CD8^+^tTILs^IM^) in randomly selected fields in the exploratory study\
**(A)** center: r=0.705, p\<0.001. **(B)** surface: r=0.568, p\<0.001.](oncotarget-09-15180-g004){#F4}

Patients' characteristics in the validation study {#s2_8}
-------------------------------------------------

The patient characteristics are listed in Table [1](#T1){ref-type="table"}. The distribution of cancer stages was as follows: stage II, 96 patients; stage III, 78 patients. All patients were followed up as described above until September 2017 or death. The median follow-up period for the survivors in this study was 62.1 months (range: 13-89). Eighteen patients died during the follow-up period due to CRC.

A survival analysis for TILs^IM^ in randomly selected fields in the validation study {#s2_9}
------------------------------------------------------------------------------------

We assessed the prognostic value of the density of TILs at the invasive margin. High-CD8^+^tTILs^IM^/sTILs^IM^ were significantly associated with high DSS rates, just as in the exploratory study (both p\<0.001) (Figure [5D, 5E](#F5){ref-type="fig"}). In addition, high-CD8^+^iTILs^IM^ tended to be associated with high DSS rates (p=0.069) (Figure [5F](#F5){ref-type="fig"}).

![Kaplan-Meier survival curves for the disease-specific survival according to the density of CD4/CD8^+^ TILs at the invasive margin (TILs^IM^) in randomly selected fields in the validation study\
**(A)** CD4^+^ tTILs^IM^. **(B)** CD4^+^ sTILs^IM^. **(C)** CD4^+^ iTILs^IM^. **(D)** CD8^+^ tTILs^IM^. **(E)** CD8^+^ sTILs^IM^. **(F)** CD8^+^ iTILs^IM^. tTILs, total TILs. sTILs, TILs in tumor stroma. iTILs, TILs intra-tumor cells.](oncotarget-09-15180-g005){#F5}

A survival analysis for TILs^IM^ in hot spots in the validation study {#s2_10}
---------------------------------------------------------------------

In the evaluation focusing on hot spots, the densities of all TILs evaluated by each method showed no prognostic significance, just as in the exploratory study (Figure [6](#F6){ref-type="fig"}).

![Kaplan-Meier survival curves for the disease-specific survival according to the density of CD4/CD8^+^ TILs at the invasive margin (TILs^IM^) focusing on hot spots in the validation study\
**(A)** CD4^+^tTILs^IM^. **(B)** CD4^+^sTILs^IM^. **(C)** CD4^+^iTILs^IM^. **(D)** CD8^+^tTILs^IM^. **(E)** CD8^+^sTILs^IM^. **(F)** CD8^+^iTILs^IM^. tTILs, total TILs. sTILs, TILs in tumor stroma. iTILs, TILs intra-tumor cells.](oncotarget-09-15180-g006){#F6}

Correlations between the density of CD8^+^tTILs^IM^ and the clinicopathological factors in the validation study {#s2_11}
---------------------------------------------------------------------------------------------------------------

The density of CD8^+^tTILs^IM^ in randomly selected fields exhibited no significant relationship with any of the clinicopathological parameters (Table [2](#T2){ref-type="table"}).

Correlations between the MMR status and the density of CD8^+^tTILs^IM^ in the validation study {#s2_12}
----------------------------------------------------------------------------------------------

The density of CD8^+^tTILs^IM^ in randomly selected fields in MMR-D patients was significantly higher than that in MMR-P patients (p=0.012) (Figure [3B](#F3){ref-type="fig"}).

Prognostic factors influencing the survival in the validation study {#s2_13}
-------------------------------------------------------------------

The correlations between the DSS and various clinicopathological factors are shown in Table [4](#T4){ref-type="table"}. A multivariate analysis indicated that lymph node metastasis (hazard ratio, 4.30; 95% confidence interval, 1.26-20.03; p=0.019) and the density of CD8^+^tTILs^IM^ in randomly selected fields (hazard ratio, 14.94; 95% confidence interval, 4.65-60.02; p\<0.001) was an independent prognostic factor for the DSS.

###### Correlations between the disease-specific survival and various clinicopathological factors in the validation study

                                                                             Univariate analysis   Multivariate analysis                                      
  -------------------------------------------------------------------------- --------------------- ----------------------- --------- --------- -------------- ---------
  Age (≥65 vs. \<65)                                                         0.916                 0.361-2.491             0.857     0.895     0.293-2.814    0.845
  Tumor depth (T4 vs. T1-3)                                                  1.813                 0.692-4.599             0.218     1.603     0.390-6.530    0.505
  Histological type (Poorly, Mucinous vs. Well, Moderately)                  6.537                 1.845-18.337            0.006     1.557     0.384-5.528    0.513
  Lymphatic involvement (Positive vs. Negative)                              8.388                 1.723-151.072           0.004     3.765     0.652-71.445   0.155
  Venous involvement (Positive vs. Negative)                                 1.872                 0.652-4.823             0.229     0.749     0.190-2.638    0.660
  Lymph node metastasis (Positive vs. Negative)                              7.053                 2.326-30.449            \<0.001   4.296     1.258-20.029   0.019
  CEA (≥5 ng/ml vs. \<5 ng/ml)                                               2.636                 1.037-7.167             0.042     2.765     0.955-8.731    0.061
  CA19-9 (≥37 U/ml vs. \<37 U/ml)                                            1.523                 0.240-5.401             0.596     2.301     0.325-10.372   0.355
  The density of CD8^+^tTILs^IM^ in randomly selected field (Low vs. High)   15.918                5.695-56.251            \<0.001   14.943    4.647-60.017   \<0.001
  Mismatch repair status (deficient vs. proficient)                          \<0.001               NA                      0.151     \<0.001   0.000-32.813   \<0.999

HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; tTILs^IM^, total tumor-infiltrating lymphocytes at the invasive margin; NA, not available.

Correlations between the density of TILs^IM^ and TILs^CT^/TILs^ST^ in the validation study {#s2_14}
------------------------------------------------------------------------------------------

The densities of CD8^+^ tTILs^CT^ and CD8^+^ tTILs^ST^ were significantly associated with that of CD8^+^tTILs^IM^ in randomly selected fields, just as in the exploratory study (TILs^CT^ (Figure [7A](#F7){ref-type="fig"}): r=0.70, p\<0.001; TILs^ST^ (Figure [7B](#F7){ref-type="fig"}): r=0.61, p\<0.001).

![The correlations between the densities of total CD8^+^TILs at the center of the tumor (CD8^+^tTILs^CT^)/at the surface of the tumor (CD8^+^tTILs^ST^) and that of total CD8^+^TILs at the invasive margin (CD8^+^tTILs^IM^) in randomly selected fields in the validation study\
**(A)** center: r=0.699, p\<0.001. **(B)** surface: r=0.610, p\<0.001.](oncotarget-09-15180-g007){#F7}

DISCUSSION {#s3}
==========

The current study showed that the densities of both total CD8^+^TILs and CD8^+^TILs in tumor stroma at the invasive margin were associated with the prognosis in patients with Stage II/III CRC. While many previous reports have found the density of TILs as evaluated by immunohistochemical staining to be a useful prognostic marker, the methodology for evaluating the density of TILs has not been standardized. To our knowledge, this is the first report to describe the detailed methodology for evaluating the density of TILs by immunohistochemical staining.

The current study demonstrated that the density of CD4^+^TILs may not be useful as a prognostic marker, while the density of CD8^+^TILs may be useful as a prognostic marker for malignancy. Although some authors have reported that CD4^+^TILs may be a prognostic predictor for malignancies \[[@R16], [@R17]\], we concluded that the density of CD4^+^TILs was not associated with the prognosis because CD4^+^ T cells can be classified into more detailed subsets, such as T helper 1 (Th1) cells, Th2 cells, Th17 cells, and regulatory T (Treg) cells, and the functions of each CD4^+^ T cell subset differ with regard to antitumor immunity. For example, Th1 cells produce cytokines, such as interferon-γ (INF-γ), which activate CD8^+^ T cells \[[@R7]\]. Therefore, Th1 cells have been reported to enhance the antitumor immune response \[[@R18]\]. However, Th2 cells seem to suppress the antitumor immune response via the activation of B cells or the production of the immunosuppressive cytokine IL-10 \[[@R7]\]. In addition, findings regarding the function of Th17 cells in antitumor immunity have been controversial. For example, some authors have reported that Th17 cells facilitate the antitumor immune response, while other authors have reported that Th17 cells accelerate tumor growth via neoangiogenesis of the tumor \[[@R7]\]. Treg cells have been reported to suppress the antitumor immune response \[[@R7]\]. In contrast, CD8^+^ T cells (cytotoxic T lymphocytes) have been reported to have direct cytotoxic effects on tumor cells via the antitumor immune response and also be strongly associated with prolonged survival \[[@R7], [@R10], [@R19]\]. Recently, Galon et al. developed the "immunoscore" as a prognostic indicator using the density of CD8^+^TILs and reported that this score might better reflect the prognosis of cancer patients than the TNM classification \[[@R6], [@R8]\].

In the current study, the average density of CD8^+^TILs evaluated in five different randomly selected fields was a strong prognostic biomarker. We considered it important to evaluate the antitumor immune status of the whole tumor by evaluating the density of TILs in multiple fields selected randomly in order to resolve the issue of the heterogeneity of the density of TILs in the tumor \[[@R20]\]. However, many previous reports have not described the methodology used to select the fields in which the density of TILs was evaluated \[[@R15], [@R21]\]. The absence of a consistent methodology for selecting fields may prevent us from accurately evaluating the antitumor immune status. The current study showed that the number of CD8^+^TILs evaluated by focusing on hot spots was not associated with the survival, although a previous report in a large cohort showed that the number of CD8^+^TILs evaluated in areas containing hot spots was significantly associated with the survival \[[@R10]\]. We considered that the number of CD8^+^TILs evaluated in large areas containing hot spots using an image analyzer well-reflected the average density of TILs (i.e. the antitumor immune status in the whole tumor) \[[@R10]\]. In contrast, the number of CD8^+^TILs evaluated by focusing on hot spots may not reflect the antitumor immune status in the whole tumor, because observers evaluated the density of CD8^+^TILs in extremely small areas (i.e. high-power fields) in the current study. We may therefore have incorrectly categorized some patients with low lymphocyte infiltration as having high lymphocyte infiltration. The density of CD8^+^TILs should be evaluated not in the fields focusing on hot spots but in those selected randomly when performing observer-based evaluations.

We found that the density of CD8^+^TILs intra-tumor cells was not a useful prognostic biomarker, despite previous reports on the prognostic utility of the density of CD8^+^TILs intra-tumor cells \[[@R22], [@R23]\]. The density of CD8^+^TILs intra-tumor cells may be unlikely to reflect differences in the antitumor immune status among patients sensitively, as the absolute number of CD8^+^TILs intra-tumor cells evaluated in high-power fields was quite low. CD8^+^TILs intra-tumor cells, which showed a markedly low density in our study, may not be a useful prognostic biomarker in the clinical setting, although CD8^+^TILs intra-tumor cells may have biological significance.

We found that evaluating the density of total CD8^+^TILs without distinguishing between TILs in tumor stroma and TILs intra-tumor cells was an ideal and easy-to-perform method in the clinical setting. Previous studies in large cohorts \[[@R10], [@R21]\] have shown that a high density of total CD8^+^TILs was associated with a good survival. Furthermore, the prognostic indicator "immunoscore" \[[@R24]\] described above included the evaluation of the density of total CD8 ^+^TILs. In our results, the number of total TILs was similar to that of TILs in tumor stroma, as the number of TILs intra-tumor cells was extremely low. We therefore considered that the evaluation of the density of total TILs was more reasonable than the evaluation of that of TILs in tumor stroma in analyses performed using an image analyzer \[[@R10], [@R15], [@R25]\], which has difficulty distinguishing between TILs intra-tumor cells and TILs in tumor stroma. Furthermore, the evaluation of total TILs without distinguishing between TILs intra-tumor cells and TILs in tumor stroma was a useful and easy-to-perform method for evaluations carried out by an observer.

High-grade MSI (MSI-H) CRC is reportedly more immunogenic with greater infiltration by immune cells than microsatellite stable (MSS) CRC because of the large number of tumor antigens produced by frameshift mutations \[[@R26], [@R27]\]. Patients with MSI-H Stage II/III CRC have been found to have a better prognosis than those with MSS CRC \[[@R28]\], because MSI-H tumors are suppressed by a strong antitumor immune response associated with MSI-H tumors. Based on these findings, the MSI status may induce a bias in the association between the density of TILs and the prognosis. Although MMR-D tumors had greater CD8^+^TIL infiltration than MMR-P tumors in the current study, relatively few CRC patients had MMR-D tumors (5.1%), and the density of CD8^+^TILs was an MMR status-independent prognostic biomarker.

In previous reports, when assessing the antitumor immunity, most researcher have evaluated the density of TILs at the invasive margin \[[@R15], [@R21]\] or the combination of the density of TILs at the invasive margin and those of TILs at the center of the tumor \[[@R8], [@R10], [@R25]\]. On the other hand, the density of TILs at the surface of the tumor in pretreatment biopsy samples of rectal cancer was recently reported to be useful as a marker for predicting the response to neoadjuvant therapy in patients with locally advanced rectal cancer \[[@R29]--[@R31]\]. However, whether or not the density of TILs at the surface of the tumor accurately reflects the antitumor immune status of the whole tumor has been unclear. The current study showed that the density of TILs at the surface of the tumor was significantly associated with that of TILs at the invasive margin. We therefore concluded that the density of TILs at the surface of the tumor may reflect the antitumor immune status to some extent and may be secondary biomarkers of the antitumor immune status. This notion supports the findings of previous reports regarding the utility of assessing the antitumor immune status by evaluating the density of TILs at the surface of the tumor in pretreatment biopsy samples of rectal cancer as a predictive marker for response to neoadjuvant therapy \[[@R29]--[@R31]\].

Several limitations associated with the present study warrant mention. First, the current study was retrospective with relatively few patients. Second, we did not evaluate the fine subsets of CD4^+^TILs and CD8^+^TILs. Future studies should investigate the significance of the fine subsets of CD4^+^cells (i.e. Th1, Th2, Th17, Treg cells) and CD8^+^cells (i.e. CD8^+^ memory T cells) in antitumor immunity. Third, the optimum methodology of evaluating the density of TILs has not been established. In the current study, we counted the absolute number of TILs in order to evaluate the antitumor immune status. However, Salgado et al. \[[@R32]\] evaluated the percentage of the area occupied by TILs in the tumor stroma area as a semiquantitative parameter (every 10%), and Richards et al. \[[@R23]\] evaluated the density of TILs semi-quantitatively as absent, weak, moderate, or strong. Applying the evaluation of TILs in the clinical setting will require determining the optimum methodology of measuring the density of TILs. Fourth, in the current study we evaluated the average number of TILs in five different randomly selected fields in the tumor in order to resolve the issue of the heterogeneity of TILs. However, this issue still remains, making it necessary to establish a better method of evaluating the antitumor immune status for the whole tumor.

CONCLUSIONS {#s4}
===========

We concluded that the best and easiest way to evaluate the density of TILs in the clinical setting may be to assess the density of total CD8^+^TILs at the invasive margin in randomly selected fields.

PATIENTS AND METHODS {#s5}
====================

Patients {#s5_1}
--------

A total of 313 patients with stage II/III CRC were enrolled in this study. All patients underwent potentially curative surgery for CRC at the Department of Surgical Oncology of Osaka City University between 2007 and 2012. Patients who received preoperative therapy, underwent emergency surgery for perforation/obstruction, or who had inflammatory bowel disease were excluded from this study.

All patients were divided into two groups: including the exploratory group, which consisted of 139 patients who underwent surgery between 2007 and 2009; and the validation group, which consisted of 174 patients who underwent surgery between 2010 and 2012.

Immunohistochemistry for CD4/CD8 {#s5_2}
--------------------------------

Surgically resected specimens were retrieved in order to perform the immunohistochemistry. All 4-μm-thick sections were deparaffined and rehydrated and then subjected to endogenous peroxidase blocking in 1% H~2~O~2~ solution in methanol for 15 minutes. Antigen retrieval was performed by autoclaving the sections at 105°C for 10 minutes in Dako Target Retrieval Solution (Dako, Glostrup, Denmark). Serum blocking was performed with antibody 10% normal rabbit serum for 10 minutes. After H~2~O~2~ and serum blocking, the slides were incubated with primary mouse monoclonal anti-CD4 antibody (1:80 dilution; Dako) at room temperature for 20 minutes, and the slides were incubated with primary mouse monoclonal anti-CD8 antibody (1:100 dilution; Dako) at room temperature for 30 minutes. The secondary antibody was biotin-labeled rabbit anti-mouse IgG, IgA, IgM (1:500; Nichirei, Tokyo, Japan). Detection was performed with a DAB kit (Histofine simple stain kit; Nichirei). The sections were counterstained with hematoxylin.

The immunohistochemical evaluation was carried out by two independent pathologists who were blinded to the clinical information. We examined the average number of TILs in 5 different fields with a light microscope at 400× magnification by the following: 1) subsets of lymphocytes (i.e. CD4^+^(Figure [8A](#F8){ref-type="fig"}) or CD8^+^(Figure [8B](#F8){ref-type="fig"})), 2) selected fields (i.e. at random or focusing on hot spots (Figure [9](#F9){ref-type="fig"})), 3) location in low-power field (Figure [9](#F9){ref-type="fig"}) (i.e. the invasive margin \[TILs^IM^\] or the center of the tumor \[TILs^CT^\] or the surface of the tumor \[TILs^ST^\]), 4) location in high-power field (Figure [10](#F10){ref-type="fig"}) (i.e. in tumor stroma \[sTILs\] or intra-tumor cells \[iTILs\] or total TILs \[tTILs: sTILs+iTILs\]). We set each median value as the cut-off value for the density of TILs evaluated by each method in the exploratory study (Table [5](#T5){ref-type="table"}). In the validation study, we also used the cut-off value used in the exploratory study. We then classified the patients into the high- and low-TILs groups.

![Immune marker expression of tumor-infiltrating lymphocytes\
**(A)** CD4. **(B)** CD8. Magnification, 400×.](oncotarget-09-15180-g008){#F8}

![Immunoreactive TILs determined at each intratumoral subsite in low-power fields (invasive margin, the center of the tumor and the surface of the tumor)\
Hot spots are indicated by an arrow.](oncotarget-09-15180-g009){#F9}

![TILs in tumor stroma and intra-tumor cells\
Arrowhead: iTILs, TILs intra-tumor cells. arrow: sTILs, TILs in tumor stroma.](oncotarget-09-15180-g010){#F10}

###### The number of TILs at the invasive margin (/field)

                           Exploratory Group   Validation Group                     
  ------------------------ ------------------- ------------------ ----------------- -----------------
  CD4 (Median \[range\])                                                            
   tTILs                   4.2 (0-36.6)        18.4 (1.2-60.4)    2.2 (0-13.8)      18.8 (4-51.0)
   sTILs                   4.2 (0-36.6)        18.4 (1.2-60.4)    2.2 (0-13.8)      18.8 (4-51.0)
   iTILs                   0 (0-0.4)           0 (0-0.2)          0 (0-2.2)         0 (0-4.4)
  CD8 (Median \[range\])                                                            
   tTILs                   7.6 (0.4-37.8)      39 (9.4-114.2)     12.5 (0.2-34.2)   32.6 (7.0-79.6)
   sTILs                   5.0 (0-29.0)        37.4 (3.8-114.2)   11.6 (0.2-29.8)   32.6 (7.0-79.6)
   iTILs                   1.6 (0-16.4)        0 (0-16.8)         0.2 (0-12.8)      0 (0-4.0)

TILs: Tumor-infiltrating lymphocytes, tTILs: total TILs (sTILs+iTILs), sTILs: TILs in tumor stroma, iTILs: TILs intra tumor cells.

Tissue microarray construction {#s5_3}
------------------------------

We constructed a tissue microarray (TMA) in order to evaluate the mismatch repair (MMR) status by immunohistochemical staining. A tissue microarray with one 3.0-mm-diameter punch core per cancer was constructed from formalin-fixed paraffin-embedded tissue blocks of all patients, as previously reported \[[@R33]\]. We ensured that the specific tumor histological type was representatively included in the TMA using Hematoxylin-Eosin-stained TMA sections.

Immunohistochemistry for mismatch repair status {#s5_4}
-----------------------------------------------

The effectiveness of an immunohistochemical analysis of the MMR proteins is reportedly similar to that of genotyping for microsatellite instability (MSI) \[[@R34]\]. Therefore, the MSI status was estimated based on the mismatch repair (MMR) status, as previously reported \[[@R35]\]. The MMR status was identified by immunohistochemical staining of MMR proteins (i.e. MLH1, MSH2, MSH6 and PMS2), as previously reported \[[@R36]\].

All 4-μm-thick TMA slides were deparaffined and rehydrated and then subjected to endogenous peroxidase blocking in 1% H~2~O~2~ solution in methanol for 15 minutes. Antigen retrieval was performed by autoclaving the sections at 121°C for 15 minutes in Dako Target Retrieval Solution (Dako). Serum blocking was performed with antibody 10% normal rabbit serum for 10 minutes. After H~2~O~2~ and serum blocking, the slides were incubated in primary antibody for 20 minutes for MLH1 (prediluted product), 20 minutes at a concentration of 1:50 for MSH2 and MSH6, and 30 minutes at a concentration of 1:40 for PMS2 at room temperature (product codes: IS079, M3639, M3646, M3647 \[all from Dako\]). The secondary antibody was biotin-labeled rabbit anti-mouse IgG, IgA, IgM (1:500; Nichirei). Detection was performed with a DAB kit (Histofine simple stain kit; Nichirei). The sections were counterstained with hematoxylin.

The MMR protein expression was evaluated by two pathologists blinded to the clinical outcomes. Normal colon tissue was used as a positive control, and positive staining within intra-tumoral immune cells was used as an internal positive control. The expression was evaluated as MMR-proficient (MMR-P) (tumor cell nuclear expression with positive immune cell expression) (Figure [11A, 11C, 11E, 11G](#F11){ref-type="fig"}) or MMR-deficient (MMR-D) (absent tumor cell nuclear expression with positive immune cell expression) (Figure [11B, 11D, 11F, 11H](#F11){ref-type="fig"}). One core was examined per patient for each MMR protein. The tumor was defined as MMR-D when one or more MMR proteins was negatively expressed.

![Immunohistochemical staining for mismatch repair proteins\
MLH1 (**A**. positive, **B**. negative). MSH2 (**C**. positive, **D**. negative). MSH6 (**E**. positive, **F**. negative). PMS2 (**G**. positive, **H**. negative). Magnification, 400×.](oncotarget-09-15180-g011){#F11}

Statistical analyses {#s5_5}
--------------------

The duration of the survival was calculated using the Kaplan-Meier method. Differences in the survival curves were assessed using the log-rank test. The significance of the correlations between TILs and the clinicopathological characteristics was analyzed using the χ^2^ test and Fisher\'s exact test. A multivariate analysis was performed according to the Cox proportional hazard model. Associations between the density of TILs^IM^ and the density of TILs^CT^/TILs^ST^ was evaluated using the Pearson\'s correlation analysis. Associations between the density of TILs in MMR-P tumor and that in MMR-D tumor were analyzed using Wilcoxon\'s rank sum test. All of the statistical analyses were conducted using JMP^®^ 13.0.0 software program (2016 SAS institute Inc., Cary, NC, USA). P values of \<0.05 were considered to indicate statistical significance.

Ethical considerations {#s5_6}
----------------------

This study conformed to the provisions of the Declaration of Helsinki. All patients were informed of the investigational nature of this study and provided their written informed consent. This retrospective study was approved by the ethics committee of Osaka City University (approved no. 3853).
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CA19

:   9-carbohydrate antigen 19-9

CEA

:   carcinoembryonic antigen

CI

:   confidence interval

CRC

:   Colorectal cancer

DSS

:   disease-specific survival

HR

:   hazard ratio

INF

:   γ-interferon-γ

iTILs

:   tumor-infiltrating lymphocytes intra-tumor cells

RFS

:   relapse-free survival

sTILs

:   tumor-infiltrating lymphocytes in tumor stroma

Th1 cells

:   T helper 1 cells

TILs

:   tumor-infiltrating lymphocytes

TILs^CT^

:   tumor-infiltrating lymphocytes at the center of the tumor

TILs^IM^

:   tumor-infiltrating lymphocytes at the invasive margin

TILs^ST^

:   tumor-infiltrating lymphocytes at the surface of the tumor

Treg cells

:   regulatory T cells

tTILs

:   total tumor-infiltrating lymphocytes
